SEC For	m 4 FORM	4	UNITED ST	ATE	s se	ECUR	ITIE	ES AND	ЕХСНА	NGE C	оммі	SSION			
				Washington, D.C. 20549								OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See						A pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							OMB Number: Estimated average hours per respon		3235-0287 len 0.5
1. Name and Address of Reporting Person* <u>DIXON WENDY L</u>					2. Issuer Name and Ticker or Trading Symbol <u>IOVANCE BIOTHERAPEUTICS, INC.</u> [IOVA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Last) (First) (Middle) C/O IOVANCE BIOTHERAPEUTICS, INC. 825 INDUSTRIAL ROAD, 4TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 06/10/2022							Officer (give title Other (specify below) below)			
(Street) SAN CARLOS CA 94070				4.	lf Amer	ndment, I	Date (of Original File	ed (Month/Da	Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(S	,	(Zip)		. 0			audian d. Di				Person			
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D				sactior	ction 2A. Deemed Execution Date,			Code (Instr. 5)			d (A) or	5. Amour Securitie Beneficia Owned F	s Form Ily (D) o ollowing (I) (Ir	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
								Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
		٦	able II - Deriv (e.g.,					uired, Dis , options,				Owned			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any				Transaction of Code (Instr. Derivative			6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y Direct (D or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Deferred Restricted Stock Unit	(1)	06/10/2022		А		51,204		(2)	(2)	Common Stock	51,204	\$0	51,204	D	

Explanation of Responses:

1. Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).

2. Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (2) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reported Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.

/s/ Wendy Dixon	06/14/2022
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.